论文部分内容阅读
通过基因工程合成重症肌无力胸腺瘤特异性 3 0kD抗原 (MGT 3 0 ) ,并研究MGT 3 0在诊断胸腺瘤重症肌无力 (MGT )中的意义。应用逆转录 聚合酶链反应 (RT PCR )技术 ,以MGT患者骨骼肌总RNA为模板 ,扩增出MGT 3 0的cDNA ;并重组到pET 3 0a载体 ;然后用大肠杆菌BL2 1诱导表达MGT 3 0蛋白 ,相对分子质量为 4 4 0 0 0。采用ELISA法检测了 2 65名正常人、2 8例经病理证实为MGT患者和 2 5例非MG其他疾病患者血清中的Titin抗体滴度。正常人与MGT患者血清中Titin抗体滴度有显著性差异 (P <0 0 1) ;2 8例MGT患者中Titin抗体阳性率达 78 6% ,2 5例非MG其它疾病患者中Titin抗体均为阴性。提示重组MGT 3 0蛋白可作为Titin抗体的特异性抗原 ,对诊断MGT有重要意义
Gene-specific synthesis of myasthenia gravis-specific 30 kD antigen (MGT 3 0 ) was performed and the significance of MGT 30 in the diagnosis of thymoma myasthenia gravis (MGT) was studied. Reverse transcriptase polymerase chain reaction (RT PCR) technique was used to generate the MGT 30 cDNA as a template and the recombinant MGT 30 cDNA was recombined into the pET 30a vector; then the E. coli BL21 was used to induce MGT 3 expression. Protein 0, with a relative molecular weight of 4400. Titin antibody titers in the serum of 2 65 normal persons, 28 pathologically confirmed MGT patients and 25 non-MG patients were detected by ELISA. Titin antibody titers were significantly different between normal and MGT patients (P <0 01). The titin antibody positive rate was 786% in 28 MGT patients. Titin antibodies were found in 25 non-MG patients. Negative. It is suggested that the recombinant MGT 30 protein can be used as a specific antigen of Titin antibody, which is important for the diagnosis of MGT.